Tuesday, May 3, 2016

Leerink downgrades Sarepta to under perform

Leerink downgrades Sarepta to under perform

May 3, 2016 by · Leave a Comment 

Tweet Leerink has downgraded Sarepta Therapeutics (NASDAQ:SRPT) to “under perform” and slashed its price target to $5 from $13. The stock closed at $17.92 on Monday. Sarpeta has been a confounding stock for which to forecast each twist and turn, but now going into the PDUFA of May 26, 2016, we believe investors have the […]

Zomedica Pharma listed on TSX Venture

Zomedica Pharma listed on TSX Venture

May 2, 2016 by · Leave a Comment 

Tweet The shares of Zomedica Pharmaceuticals (TSX-V:ZOM), a veterinary pharmaceutical company, have been listed on TSX Venture Exchange under the symbol, ZOM. “With our shares trading on TSX-V, Zomedica has a more-efficient method for raising capital to bring our veterinarian-focused products to market while concurrently delivering liquidity for shareholders,” president and CEO, Gerald Solensky, Jr., […]

Nobilis Health launches bundled payment and technology unit

Nobilis Health launches bundled payment and technology unit

May 2, 2016 by · Leave a Comment 

Tweet Nobilis Health (NYSE MKT:HLTH; TSX:NHC) has launched a comprehensive technology platform that will develop new payment and delivery methodologies to enhance value for patients, payers, and providers across the continuum of care. The new unit will be called, Concertis, and will be headed by Marissa Arreola, a former health law partner at the firm […]

Canaccord ups Spectranetics price target to $23.50

Canaccord ups Spectranetics price target to $23.50

April 29, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has raised its price target on Spectranetics (NASDAQ:SPNC) to $23.50 from $20. The stock closed at $16.68 on Thursday. “Our bullish conviction heading into the Q1 print was validated by the strong quarterly performance that reflected a continuation of the positive trends from the second half of 2015,” writes analyst Jason Mills. […]

Profound Medical sells first TULSA-PRO device

Profound Medical sells first TULSA-PRO device

April 28, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has made the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically driven ultrasound and closed-loop thermal feedback control, providing a highly precise treatment tailored to patient-specific anatomy and pathology. TULSA-PRO has demonstrated accurate and precise ablation […]

GeneNews closes note financing with Alumina

GeneNews closes note financing with Alumina

April 28, 2016 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has executed a definitive financing agreement with Alumina Partners for a second tranche of a non-brokered private placement. Under the accord, GeneNews will draw down on $10-million in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period. The initial draw will be limited to $200,000 […]

Ocular Therapeutix to initiate Phase 3 program with OTX-TP

Ocular Therapeutix to initiate Phase 3 program with OTX-TP

April 27, 2016 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) has completed an end-of-Phase 2 review with the FDA for its sustained release travoprost product candidate, OTX-TP, for the treatment of glaucoma and ocular hypertension and intends to initiate the first of two Phase 3 clinical trials during the third quarter of 2016. The FDA has stated that it agrees with […]

Novadaq posts 52% jump in Q1 revenue

Novadaq posts 52% jump in Q1 revenue

April 27, 2016 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported first quarter revenue of $17.7-million, up 52%, from $11.7-million a year ago. Total direct sales in the quarter rose by $6.1-million, or 71%, and total partnered/international sales declined by $100,000, compared with the year earlier period. The company estimates that the number of procedures performed using SPY technology systems […]

HCW starts Strongbridge Biopharma at buy

HCW starts Strongbridge Biopharma at buy

April 27, 2016 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday. “Within the span of two years, Strongbridge has made material progress to strengthen its rare endocrine portfolio and had strategically planted its footing in a Cushing’s syndrome asset with comparatively […]

Transition Therapeutics begins Phase 2 SARM study

Transition Therapeutics begins Phase 2 SARM study

April 26, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701. The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue/low vitality, and physical dysfunction in men who have […]

Next Page »

Email Newsletters with Constant Contact
Google+